101,800 Shares in 10x Genomics $TXG Bought by Capricorn Fund Managers Ltd

Capricorn Fund Managers Ltd bought a new stake in 10x Genomics (NASDAQ:TXG) during the 1st quarter, HoldingsChannel reports. The firm bought 101,800 shares of the company’s stock, valued at approximately $2,161,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Geneos Wealth Management Inc. acquired a new position in shares of 10x Genomics in the 4th quarter valued at about $38,000. Larson Financial Group LLC lifted its stake in 10x Genomics by 164.4% in the fourth quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock valued at $39,000 after buying an additional 1,470 shares during the period. Van ECK Associates Corp boosted its holdings in shares of 10x Genomics by 85.9% during the 4th quarter. Van ECK Associates Corp now owns 3,668 shares of the company’s stock worth $60,000 after buying an additional 1,695 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of 10x Genomics by 28.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,660 shares of the company’s stock worth $92,000 after buying an additional 1,237 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in shares of 10x Genomics by 203.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after buying an additional 5,025 shares during the period. Institutional investors and hedge funds own 84.68% of the company’s stock.

Wall Street Analysts Forecast Growth

TXG has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of 10x Genomics from $17.00 to $20.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a research note on Wednesday, June 24th. Morgan Stanley raised their price target on shares of 10x Genomics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 12th. Bank of America lifted their price target on shares of 10x Genomics from $21.00 to $30.00 and gave the company a “neutral” rating in a research note on Monday, April 20th. Finally, Canaccord Genuity Group upped their price objective on shares of 10x Genomics from $22.00 to $32.00 and gave the company a “buy” rating in a report on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, 10x Genomics presently has an average rating of “Hold” and a consensus price target of $24.00.

10x Genomics Stock Up 3.2%

NASDAQ TXG opened at $38.34 on Wednesday. The company has a market cap of $4.87 billion, a price-to-earnings ratio of -225.53 and a beta of 2.12. 10x Genomics has a 52 week low of $11.16 and a 52 week high of $38.68. The business has a 50 day moving average price of $27.13 and a 200-day moving average price of $22.39.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.19. 10x Genomics had a negative return on equity of 2.86% and a negative net margin of 3.55%.The company had revenue of $150.84 million for the quarter, compared to analysts’ expectations of $146.41 million. During the same period last year, the business earned ($0.28) EPS. 10x Genomics’s quarterly revenue was up 9.4% compared to the same quarter last year. On average, equities research analysts anticipate that 10x Genomics will post -0.79 earnings per share for the current year.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 11,595 shares of the company’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $24.44, for a total transaction of $283,381.80. Following the transaction, the insider owned 502,000 shares in the company, valued at approximately $12,268,880. This represents a 2.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Taich sold 15,098 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $24.44, for a total transaction of $368,995.12. Following the completion of the transaction, the chief financial officer directly owned 379,898 shares in the company, valued at $9,284,707.12. This trade represents a 3.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 96,309 shares of company stock worth $2,704,157. Company insiders own 8.84% of the company’s stock.

10x Genomics Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.